Categories: DNANews

CellarisBio Announces “CHALLENGING TARGET AWARD” to Promote Innovation in Drug Discovery

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ — CellarisBio breaks ground with an announcement of “Challenging Target Award” to foster innovation in the space of challenging therapeutic targets. The award is designed to de-risk & accelerate first-in-class and best-in-class drug discovery programs. It will provide the awardee with exclusive access to CellarisBio’s MICRO-TAG cell target engagement platform. The platform enables:

  • Drug discovery using DNA-Encoded Libraries (DELs),
  • Hit-to-lead optimization,
  • Real-time analysis for mechanism-of-action studies.

The award will launch on January 15th, 2025, at https://cellarisbio.com/award and the winner will be announced on April 15th, 2025.

Our mission is to expand the druggable proteome for discovery of precision therapeutics. We are particularly keen on challenging drug targets, proteins that have been known as undruggable. We tackle them within the native environment of the cell.” stated Elmar Nurmemmedov, cofounder and CEO at CellarisBio. “There are more than 9000 undiscovered therapies that are locked behind challenging drug targets. We pledge to work closely with ambitious biotechs to unlock life-saving therapies of the future.” Elmar added.

“In the recent years, we have witnessed an evolution of drug discovery technologies and therapeutic modalities. It is now becoming increasingly imperative to use live cells as filters to de-risk and accelerate therapeutic findings. Demonstration of direct drug target engagement within the cellular environment is indispensable for drug pharmacology. The “Challenging Target Award” is agnostic to the target family, disease area and how drug candidates were discovered.” said Ivan Babic, cofounder at CellarisBio.

Watch the official CellarisBio trailer here: Youtube

Award link: CellarisBio

About CellarisBio
CellarisBio is a techbio company, developing the next-gen cell target engagement technology, delivered as MICRO-TAG™ platform. Based at Biovista labs in San Diego, CellarisBio, the company capitalizes on several patents protecting the technology. CellarisBio has recently fostered multiple partnerships with companies around the world.

Contact:
hi@cellarisbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellarisbio-announces-challenging-target-award-to-promote-innovation-in-drug-discovery-302332222.html

SOURCE CellarisBio

Staff

Recent Posts

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

1 hour ago

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

1 hour ago

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

4 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

4 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

4 hours ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

4 hours ago